1- (1-Benzothiophen-4-yl) piperazine Hydrochloride CAS 913614-18-3 Tsarkake>98.0% (HPLC) Brexpiprazole Intermediate Factory
Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo [b] thiophene CAS 5118-13-8
1- (1-Benzothiophen-4-yl) Piperazine Hydrochloride CAS 913614-18-3
7- (4-Chlorobutoxy) quinolin-2(1H) -daya CAS 913613-82-8
4-Chlorobenzo [b] thiophene CAS 66490-33-3
Sunan Sinadari | 1- (1-Benzothiophen-4-yl) Piperazine Hydrochloride |
Makamantu | Brexpiprazole Matsakaici 2;1-Benzo[b]thien-4-yl-Piperazine Hydrochloride;1-Benzo[b]thien-4-ylpiperazine Monohydrochloride |
Lambar CAS | 913614-18-3 |
Lambar CAT | Saukewa: RF-PI1034 |
Matsayin Hannun jari | A cikin Hannun jari, Ƙarfin Ƙirƙirar 100MT/Shekara |
Tsarin kwayoyin halitta | Saukewa: C12H15ClN2S |
Nauyin Kwayoyin Halitta | 254.7789 |
Alamar | Ruifu Chemical |
Abu | Ƙayyadaddun bayanai |
Bayyanar | Fari zuwa Kashe-Farin Foda |
Ganewa | Lokacin riƙe samfurin yayi daidai da na ƙa'idar tunani |
Tsarkake / Hanyar Bincike | > 99.0% (HPLC) |
Asara akan bushewa | <0.50% |
Ruwa (KF) | <0.50% |
Ragowa akan Ignition | <0.20% |
Abubuwa masu alaƙa | (HPLC) |
Duk wani Rashin Tsabtace Mutum | <0.50% |
Jimlar ƙazanta | <1.00% |
Infrared Spectrum | Yayi daidai da Tsarin |
Abubuwan da aka bayar na Proton NMR Spectrum | Yayi daidai da Tsarin |
Matsayin Gwaji | Matsayin Kasuwanci |
Amfani | Matsakaicin Brexpiprazole (CAS: 913611-97-9) |
Kunshin: Bottle, Aluminum tsare jakar, 25kg / kwali Drum, ko bisa ga abokin ciniki ta bukata
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi
1- (1-Benzothiophen-4-yl) piperazine Hydrochloride (CAS: 913614-18-3) matsakaici ne na Brexpiprazole (CAS: 913611-97-9).Brexpiprazole wani nau'i ne na antipsychotic mai lalacewa.Yana da mai karɓa na D2 mai karɓa na agonist.A matsayin novel Serotonin-dopamine aiki modulator, ana iya amfani da shi don maganin schizophrenia, da kuma maganin haɗin gwiwa don baƙin ciki.Hakanan yana iya ba da inganci da juriya akan kafaffen jiyya na rashin jin daɗi (MDD).Magungunan yana nuna bayanin martaba na musamman na pharmacological, yana aiki azaman agonist na serotonin 5-HT1A da masu karɓa na dopamine D2 kuma a matsayin cikakken antagonist na 5-HT2A da noradrenaline α1B / 2C masu karɓa, tare da alaƙar haɗin kai na subnanomolar iri ɗaya.Magungunan, wanda Otsuka da Lundbeck suka kirkira, an amince da shi a cikin 2015 ta FDA don maganin schizophrenia da kuma a matsayin ƙarin magani don damuwa.